United States· US:61958-2401_6ce7dd60-defa-4530-bff3-de03885e318a
Vosevi
A sofosbuvir, velpatasvir and voxilaprevir product containing sofosbuvir; velpatasvir; voxilaprevir, registered in United States by Gilead Sciences, Inc.. The same ATC class is registered in 13 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Sofosbuvir, velpatasvir and voxilaprevir is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AP56 (sofosbuvir, velpatasvir and voxilaprevir), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 10 of them publish a price we can compare per daily dose
Sofosbuvir, velpatasvir and voxilaprevir · ATC J05AP56
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of sofosbuvir, velpatasvir and voxilaprevir costs, country by country.
Normalised to the WHO defined daily dose (0.4 g), the median price runs from $447.39 in Switzerland to $1097.10 in Italy — a ×2.5 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Sofosbuvir, velpatasvir and voxilaprevir · price per daily dose (0.4 g)
USD · FX 28 Sept 2026
- IT Italy$1097.10
- CH Switzerland$447.39
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR
- Manufacturer
- Gilead Sciences, Inc.
- Country
- United States (US)
- ATC code
- J05AP56
- ATC class
- Sofosbuvir, velpatasvir and voxilaprevir
- Defined daily dose
- 0.4 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc11619582401128 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-2401-1)
- ndc1161958-2401-1
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sofosbuvir, velpatasvir and voxilaprevir in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaVOSEVIGilead Sciences Ireland UC, Carrigtohill
- PolandVoseviGilead Sciences Ireland UC
- SwedenVosevi 200 mg/50 mg/50 mg Filmdragerad tablettGilead Sciences Ireland UC
- FinlandVoseviGilead Sciences Ireland UC
- IrelandVosevi 200 mg/50 mg/50 mg film-coated tabletsGilead Sciences Ireland UC
- IcelandVoseviGilead Sciences Ireland UC*
- NetherlandsVosevi 200 mg/50 mg/50 mg, filmomhulde tablettenGilead Sciences Ireland UC
- SwitzerlandVosevi, FilmtablettenGilead Sciences Switzerland Sàrl
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vosevi
- Liechtenstein · Vosevi
- Norway · Vosevi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/af408d07-e8f2-4bc4-bd3c-2ade575c4d6b GET /v1/drugs/af408d07-e8f2-4bc4-bd3c-2ade575c4d6b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "400; 100; 100",
"substance": "SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR",
"productndc": "61958-2401",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1; mg/1; mg/1",
"application_number": "NDA209195",
"marketing_category": "NDA"
}See everything about sofosbuvir, velpatasvir and voxilaprevir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.